Objective: The aim of this study was to evaluate the therapeutic efficacy of compound Danshen dropping pills in the adjunctive treatment of diabetic nephropathy. Method: Retrieved from the Cochrane Library (Issue 3

2013)

Medline

CBM

CNKI

VIP and Wangfang database online version

RCT

from January 1990 to July 2014

about compound Danshen dropping pills on the basis of conventional treatment for diabetic nephropathy with conventional treatment as control group were collected. Meta-analysis of included trials was performed using Rev Man 5.2 software. Result: A total of 19 studies were included

involving 1 491 patients. There were good balance between 19 RCTs

the quality evaluation of 7 RCTs scored class B

with the rest for class C. Meta-analysis showed that experimental group and control group had statistically difference in clinical efficacy[OR=6.17

95%CI(3.42

11.13)

P <0.05]

UAER[MD=-15.95

95%CI(-21.69

-10.20)

P< 0.01]

and 24-hour urinary protein excretion[MD=-0.06

95%CI(-0.08

-0.03)

P< 0.01]. But there was no statistically difference in Creatinine [MD=4.69

95%CI(-0.04

9.42)

P=0.05] and Blood glucose [MD=-0.04

95%CI(-0.17

0.08)

P >0.05]. Conclusion: The existing evidence show that

to the DN patients

compound Danshen dropping pills has no significant impact on renal function and blood glucose

but it can reduce the Urine protein level. The poor methodological quality of included studies seriously weakened the validity of the meta-analysis. So the efficacy of Compound Danshen dropping pills in the treatment of diabetic nephropathy should be determined by more high quality RCTs.